公司概况 - 公司是一家专注于开发基于CRISPR/Cas9技术的潜在治疗方法的领先临床阶段基因编辑公司[585] 财务表现 - 合作收入在2022年12月31日的年度中增加了1,906.8万美元，达到了5,212.1万美元[591] - 研发支出在2022年12月31日的年度中增加了1.90172亿美元，达到了4.19979亿美元[592] - 总体而言，公司在2022年12月31日的年度中净亏损为2.067亿美元[591] - 公司的现金、现金等价物和可市场交易证券总额截至2022年12月31日为12.62亿美元[597] - 公司通过合作协议、首次公开募股、跟投公开募股等方式筹集了总计23.952亿美元资金以支持运营[597] - 公司在2022年12月完成了一项公开发行，募集了3.379亿美元的净收益[599] - 公司在2022年发行了3,395,339股普通股，募集了1.89亿美元的净收益[602] 现金流和投资 - 公司的现金流情况显示，2022年度经营活动产生的净现金流为负333.3百万美元，2021年度为负225.0百万美元[607] - 2022年度公司的投资活动产生的净现金为正160.3百万美元，主要是由于市场证券到期产生的647.6百万美元，部分抵消了购买市场证券的429.0百万美元[609] - 2022年度公司的融资活动产生的净现金为正583.0百万美元，主要是由于公司通过普通股跟进融资获得了337.9百万美元的净收益[610] 风险管理 - 公司截至2022年12月31日拥有现金等价物、受限制的现金等价物和市场证券共计12.73亿美元，主要包括计息货币市场账户、逆回购协议、公司和金融机构债券、美国国债和其他政府债券以及资产支持证券[628] - 公司主要面临的市场风险是利率敏感性，受美国利率总体水平变化影响较大，特别是因为公司的投资主要在市场证券中[628] - 公司认为，由于投资组合的短期持续时间和投资的低风险特性，即使利率立即变动100个基点，也不会对投资组合的公允市场价值产生重大影响。然而，利率下降将减少未来的投资收入[628] - 公司没有任何外币或衍生金融工具，通货膨胀主要通过增加劳动力成本、临床试验成本影响公司，公司认为通货膨胀在2022年12月31日结束的年度对其运营结果没有产生重大影响[629]

Intellia is Leading the Genome Editing Revolution Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Corporate Overview NOVEMBER 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's belief ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2022 Results Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate Communications John Leonard - President and Chief Executive Officer David Lebwohl - Executive Vice President and Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer Glenn Goddard - Executive Vice President and Chief Financial Officer Conference Call Participants Ma ...

Intellia is Leading the Genome Editing Revolution Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Corporate Overview SEPTEMBER 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's belie ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2022 Results Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate Communications John Leonard - President and Chief Executive Officer David Lebwohl - Executive Vice President and Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer Glenn Goddard - Executive Vice President and Chief Financial Officer Conference Call Participants Joon ...

Intellia is Leading the Genome Editing Revolution Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Corporate Overview MAY 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Ian Karp - SVP, IR & Corporate Communications John Leonard - President, CEO & Director David Lebwohl - EVP & Chief Medical Officer Laura Sepp-Lorenzino - EVP & Chief Scientific Officer Glenn Goddard - EVP, CFO & Treasurer Conference Call Participants Swapnil Malekar - Piper Sandler & Co. Maurice Raycroft - Jefferies Dae Gon Ha - Stifel, Nicolaus & Company Salveen Richter - Goldman Sachs Gro ...

Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Intellia is Leading the Genome Editing Revolution Corporate Overview MARCH 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs a ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2021 Earnings Conference Call February 24, 2022 8:00 AM ET Company Participants Ian Karp ??? Senior Vice President-Investor Relations and Corporate Communications John Leonard ??? Chief Executive Officer Glenn Goddard ??? Chief Financial Officer David Lebwohl ??? Chief Medical Officer Laura Sepp-Lorenzino ??? Chief Scientific Officer Conference Call Participants Joon Lee ??? Truist Maury Raycroft ??? Jefferies Greco Song ??? SVB Leerink Swapnil Malekar ??? Piper ...

Bill, living with transthyretin amyloidosis, and his wife, Maura o real Corporate Overview November 2021 THERAPEUTIC 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding our: abili ...